Among the quieter effects of GLP-1 medicines is one nobody markets: blood pressure comes down. The effect is not a rumor; it is printed in the clinical studies tables of the prescribing labels, with millimeters of mercury, placebo comparisons and confidence intervals. What the labels show is modest and consistent, and it comes with a second number moving the other way, which is heart rate, and with an adverse reaction entry that explains why prescribers pay attention.
This article walks through those tables for Wegovy and Zepbound, sizes the effect honestly, and explains the practical consequence for people who were already taking a blood pressure medicine before they started. It does not interpret your readings, and it is not suggesting that anyone adjust anything.
What the trial tables show
In the Wegovy trial for weight reduction, where the average starting systolic pressure was 131 mmHg, systolic pressure changed by 0.5 mmHg on placebo and 3.8 mmHg on Wegovy: a difference from placebo of 3.3 mmHg. Diastolic pressure moved less, by 1.0 mmHg on Wegovy against 0.5 on placebo, a difference of 0.5 mmHg. Other Wegovy trial tables tell the same story at different volumes, with systolic differences from placebo of 5.1, 3.4 and 3.9 mmHg, and diastolic differences of 2.4, 0.7 and 2.2 mmHg.
Notice what these figures are: differences between large groups of trial participants, averaged. They are what happened on average to people who took the medicine, compared with people who took placebo, in studies that enrolled people with particular starting blood pressures. They are not a forecast for any individual, and they are not a target.
The tirzepatide tables for Zepbound, where the average starting systolic pressure was around 123 mmHg, show a slightly larger movement. Systolic pressure changed from baseline by 6.6, 7.7 and 7.4 mmHg across the Zepbound doses, against 1.0 mmHg on placebo. That gives differences from placebo of 5.6 mmHg, with a 95 percent confidence interval of 7.2 to 3.9 below zero, of 6.7 mmHg, interval 8.4 to 5.0, and of 6.4 mmHg, interval 8.0 to 4.8. Another Zepbound table showed a systolic difference from placebo of 8.6 mmHg, interval 11.3 to 6.0, and a diastolic difference of 5.3 mmHg, interval 6.9 to 3.7.
The confidence intervals are worth a sentence of translation. An interval that sits entirely below zero means the average effect ran in the same direction across the trial's statistical analysis; it says nothing about the size of any one person's change. These are group statistics, and the honest summary of both products is the same: blood pressure fell, by a few millimeters of mercury more than placebo.
Sizing the effect honestly
A few millimeters of mercury is a real group effect and a small one for any individual. It is not trivial: measured across thousands of trial participants, the movement was consistent enough to be printed with confidence intervals. It is also not large, and describing it as a transformation would misread the tables. Both things are true at once, which is uncomfortable for a headline and fine for a paragraph.
The other honest point is about the baselines. These trials enrolled people whose average starting systolic pressures were 131 mmHg for the Wegovy weight reduction trial and around 123 mmHg for the Zepbound trials. Group averages from populations like those do not transfer to any particular reader, which is one reason this article reports numbers and never interprets what a home monitor is showing.
GLP 1 Tracker AppDoses, side effects and the weight trend, dated and kept on your own phone. The record behind the questions your prescriber actually asks.
Get the app
Heart rate moves the other way
The most interesting detail in these tables is not the blood pressure row at all. In the same Wegovy table where systolic pressure fell 3.3 mmHg more than placebo, heart rate rose 3.8 beats per minute on Wegovy against 0.7 on placebo, a difference of 3.1 bpm. In a Zepbound table the pulse rate difference from placebo was 1.8 bpm, with an interval of 3.4 to 0.3. Blood pressure down, heart rate up, in the same people, in the same trials.
That pairing is worth a page of its own, because the heart rate side has its own label warnings, its own numbers and its own set of worried wearable owners. It has one: Why Your Resting Heart Rate May Be Higher.
Hypotension on the label, and who saw it
The Wegovy label carries an adverse reactions entry that turns the trial averages into something a prescriber can use. Adverse reactions related to hypotension, covering hypotension, orthostatic hypotension and decreased blood pressure, were reported in 1.3 percent of Wegovy treated adult patients versus 0.4 percent of placebo treated patients in the weight reduction trials, and syncope, fainting, was reported in 0.8 percent versus 0.2 percent.
The label also explains both why and who. Some reactions were related to gastrointestinal adverse reactions and volume loss associated with Wegovy: fluid lost to nausea, vomiting or diarrhea can pull pressure down on its own. And hypotension and orthostatic hypotension were more frequently seen in patients on concomitant antihypertensive therapy, meaning people already taking a blood pressure medicine.
That last sentence is the practical heart of the article. Someone already taking a blood pressure medicine who then loses substantial weight may find their blood pressure running lower than their prescription assumes. That is why prescribers revisit those medicines as weight comes down, and revisiting them is a prescriber's job, never a reader's. Nothing here suggests anyone adjust anything.
The symptom people actually notice is light-headedness on standing, and it has its own page about what a dated log can reveal: Dizziness on a GLP-1: What Your Log Can Reveal. Dehydration from gastrointestinal losses makes it more likely, which ties into GLP-1s and Your Kidneys: Why Dehydration Is the Risk and Electrolytes on a GLP-1: When Water Alone Is Not Enough.
Not the same as the outcome trials
One distinction matters before these numbers get folded into a headline. Blood pressure falling in a trial table is a measurement; the cardiovascular outcome indications are something else entirely, built by counting heart attacks, strokes and deaths over years in defined populations. A lower average blood pressure does not by itself explain an outcome result, and the outcome trials have their own article in GLP-1s and the Heart: What the Outcome Trials Showed. Keeping the two kinds of evidence separate is what keeps a page like this honest.
Finally, the practical piece. Home readings are a thing people bring to appointments, and a record of them is useful. GLP 1 Tracker logs weight, doses and notes rather than blood pressure, so the app is not the place for cuff readings, but the record it does hold, doses, side effects and the weight trend, is exactly the context a prescriber wants next to them. Making an appointment count is its own skill, covered in Make Your Next Appointment Count: Bringing Data to the Doctor, and the lab work that often accompanies these conversations is mapped in Blood Work on a GLP-1: Numbers Worth Keeping.
Frequently asked questions
Does blood pressure go down on a GLP-1?
In the trials, yes, by a modest amount. In the Wegovy weight reduction trial, systolic pressure fell 3.8 mmHg on Wegovy against 0.5 on placebo, a difference of 3.3 mmHg, and in other Wegovy tables the systolic differences from placebo were 5.1, 3.4 and 3.9 mmHg. These are group averages from trials with particular starting blood pressures, and any individual's numbers belong with their clinician. Nothing here suggests a target or a threshold for anyone.
How much did blood pressure fall in the Zepbound trials?
Per the prescribing information, systolic pressure fell 6.6, 7.7 and 7.4 mmHg from baseline across Zepbound doses against 1.0 on placebo, giving differences from placebo of 5.6, 6.7 and 6.4 mmHg, and another trial table showed a systolic difference of 8.6 mmHg and a diastolic difference of 5.3 mmHg. Those are trial averages, not predictions for any one person. The same tables show heart rate rising while blood pressure fell.
Should I change my blood pressure medicine if my readings are lower now?
That decision belongs to a prescriber, always. The Wegovy label reports that hypotension, orthostatic hypotension and decreased blood pressure were seen in 1.3 percent of treated adults versus 0.4 percent on placebo, and that these reactions were more frequently seen in patients on concomitant antihypertensive therapy. That is why prescribers revisit those medicines as weight comes down. No reader should adjust, pause or stop anything on their own.
Why do I feel light-headed when I stand up on my GLP-1?
Light-headedness on standing is the symptom people mention most with this subject, and the label offers context rather than a diagnosis: some hypotension reports were related to gastrointestinal adverse reactions and volume loss, meaning fluid lost to nausea, vomiting or diarrhea can contribute. Dehydration is worth avoiding for many reasons on these medicines. Any dizziness that is new, repeated or severe belongs with your clinician, and a dated log of when it happens makes that conversation shorter.
Does the app track blood pressure?
No. GLP 1 Tracker logs GLP-1 doses, weight, food and activity, side effects with severity, and notes, and it reads weight, steps, active energy and water from Apple Health. It does not have a blood pressure feature. Home readings are still worth bringing to appointments by whatever means you keep them, and the record a prescriber tends to want, doses, side effects and the weight trend, is what the app holds.